WALTHAM, Mass., May 10, 2018 (GLOBE NEWSWIRE) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, announced its financial and operational results for the quarter ended March 31, 2018. “The preparation for top-line data and the NeoCart Biologics License Application […]

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone